{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:57:58Z","timestamp":1771383478126,"version":"3.50.1"},"reference-count":6,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2011,12,20]],"date-time":"2011-12-20T00:00:00Z","timestamp":1324339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Classic Kaposi\u2019s sarcoma (CKS) affects an elderly population; it is important to have effective treatment options with high activity and relatively low toxicity, and availability to be used for long periods.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> We investigated the activity and safety of single\u2010agent etoposide with an oral administration schedule in patients with advanced CKS.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Histologically confirmed, CKS patients were eligible for study. All had a negative test for HIV and good performance status. All patients received oral etoposide 50\u2003mg twice daily for 10\u2003days every 3\u2003weeks.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Thirty patients (median age 66 and 22 males) were enrolled into the study. The majority of them had non\u2010metastatic, local advanced disease and symptoms in nearly half of patients. Complete and partial responses were observed in 10% and 77% of patients, respectively, giving an overall response rate of 87%. Stable disease occurred in the other 13% of patients. Treatment was well tolerated. Grade IV toxicity was not observed. Haematological toxicity was the principal dose\u2010limiting side effect. Severe leucopaenia and neutropaenia were observed in 7% and 10% of patients respectively. No patient was complicated by febrile neutropaenia. Mild\u2010moderate anaemia observed frequently, but only 3% of patients had severe anaemia and severe thrombocytopaenia was not observed. The 5\u2010year overall survival rate was 92%.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Single\u2010agent oral etoposide is an effective treatment option and is acceptably toxic and easily administered. Therefore, we recommend the single agent of oral etoposide as the first\u2010line chemotherapy for advanced CKS.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2011.04404.x","type":"journal-article","created":{"date-parts":[[2011,12,20]],"date-time":"2011-12-20T17:30:05Z","timestamp":1324402205000},"page":"789-792","source":"Crossref","is-referenced-by-count":17,"title":["Oral etoposide as first\u2010line therapy in the treatment of patients with advanced classic Kaposi\u2019s sarcoma (CKS): a single\u2010arm trial (oral etoposide in CKS)"],"prefix":"10.1111","volume":"27","author":[{"given":"F.","family":"Tas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,12,20]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004063421407"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2008.06.007"},{"issue":"14","key":"e_1_2_5_4_2","first-page":"36","article-title":"The activity of 10\u2010, 14\u2010, and 21\u2010day schedules of single\u2010agent etoposide in previously untreated patients with extensive SCLC","volume":"19","author":"Clark PI","year":"1992","journal-title":"Semin Oncol"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.12.038"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000248608"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19941115)74:10<2873::AID-CNCR2820741021>3.0.CO;2-1"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2011.04404.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2011.04404.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T11:26:08Z","timestamp":1697369168000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2011.04404.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,20]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/j.1468-3083.2011.04404.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04404.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,20]]}}}